154
Participants
Start Date
December 1, 2017
Primary Completion Date
October 18, 2022
Study Completion Date
October 18, 2022
Intravenous ketamine
Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from depression.
Computer-based Cognitive Training
"Computer-based Cognitive Training will be delivered following intravenous ketamine to test whether learning during a post-ketamine window of opportunity might extend relief from depression."
Western Psychiatric Institute and Clinic, Pittsburgh
National Institute of Mental Health (NIMH)
NIH
Rebecca Price
OTHER